{"entity":{"id":"abclon","kind":"company","name":"AbClon","aka":["AbClon Inc.","앱클론","KOSDAQ:174900"],"tldr":"AbClon is a South Korean antibody and cell-therapy company whose CD19 CAR-T AT101 uses a newly discovered antibody binder and has shown high response rates in relapsed B-cell lymphoma.","summary":"AbClon, listed on KOSDAQ, discovers antibodies against novel epitopes and develops them as therapeutics and CAR-T cells. AT101 is an autologous CD19 CAR-T built on the h1218 antibody, which binds a different epitope of CD19 from the FMC63 binder used in approved products; a phase 1 trial in relapsed or refractory B-cell non-Hodgkin lymphoma reported complete responses in most patients at the higher doses and a phase 2 trial is under way in Korea. AbClon also develops the HER2 antibody AC101 and a switchable CAR-T platform.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.abclon.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["at101"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Seoul","country":"KR","companyType":"cell-therapy","website":"https://www.abclon.com/","ticker":"KOSDAQ:174900","founded":2010,"stage":"public","investors":[],"funding":[]},"route":"/companies/abclon/","neighbours":{"drug":[{"id":"at101","kind":"drug","name":"AT101","route":"/drugs/at101/"}]}}